Tretinoin ( DrugBank: Tretinoin )

3 diseases

2. 筋萎縮性側索硬化症

臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00919555 (ClinicalTrials.gov)	June 2008	8/6/2009	Combination Therapy in Amyotrophic Lateral Sclerosis (ALS)	Phase IIA Trial: Tretinoin and Pioglitazone HCL Combination Therapy in Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: Pioglitazone and Tretinoin;Drug: Tretinoin and Pioglitazone HCL;Drug: Placebo	Phoenix Neurological Associates, LTD	NULL	Completed	18 Years	85 Years	Both	28	Phase 1/Phase 2	United States

臨床試験数 : 271 / 薬物数 : 163 - (DrugBank : 49) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 106

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000039675	2021-01-01	2020-11-05	Phase II clinical trial of the superiority of all-trans retinoic acid in the treament of paroxysmal ...	Phase II clinical trial of the superiority of all-trans retinoic acid in the treament of paroxysmal ...	paroxysmal nocturnal hemoglobinuria	experimental group:Tretinoin0.33mg/kg.d; methylprednisolone 0.8mg/kg.d;Control test:methylprednisolo ...	Department of Hematology, Second Medical Center, Chinese PLA General Hospital	NULL	Recruiting	14	80	Both	experimental group:10;Control test:10;	Phase 2	Chinese

臨床試験数 : 203 / 薬物数 : 191 - (DrugBank : 51) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 128

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-004019-29-IT (EUCTR)	15/07/2021	07/10/2020	Italian study to evaluate the efficacy of retinoic acid and cabergoline therapy in combination in Cu ...	Medical combination therapy with retinoic acid and cabergoline in ACTH-secreting pituitary adenoma: ...	Cushing's disease in patients in whom pituitary surgery has not been curative or in situations where ...	Trade Name: Dostinex Product Name: Cabergolina Product Code: [G02CB03] INN or Proposed INN: CABERGOLINA ...	Dipartimento di Medicina-DIMED, università di Padova	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	Italy
2	EUCTR2008-006379-65-IT (EUCTR)	27/10/2008	12/11/2008	Evaluation of the benefit-risk profile of retinoic acid in the treatment of Cushing`s disease - Reti ...	Evaluation of the benefit-risk profile of retinoic acid in the treatment of Cushing`s disease - Reti ...	sperimentation only in patients	INN or Proposed INN: Tretinoin	ISTITUTO AUXOLOGICO ITALIANO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy